FDA Approves BUPRENORPHINE HYDROCHLORIDE — PAI Holdings, LLC dba PAI Pharma

PAI Holdings, LLC has received FDA approval for its ANDA for buprenorphine hydrochloride, solidifying its position in the critical opioid addiction treatment market and increasing availability for sublingual administration. This clearance positions PAI Pharma to compete against dominant manufacturers amid the ongoing shortage of essential medications for opioid use disorder.